NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 388 filers reported holding NEKTAR THERAPEUTICS in Q3 2018. The put-call ratio across all filers is 0.59 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $255,000 | +18.6% | 79,706 | +40.7% | 0.00% | 0.0% |
| Q2 2022 | $215,000 | -10.4% | 56,660 | +737.5% | 0.00% | -50.0% |
| Q2 2019 | $240,000 | -8.4% | 6,765 | -13.3% | 0.00% | 0.0% |
| Q1 2019 | $262,000 | -44.3% | 7,803 | +1.2% | 0.00% | -33.3% |
| Q3 2018 | $470,000 | -49.0% | 7,714 | -59.1% | 0.00% | -76.9% |
| Q2 2018 | $921,000 | -60.5% | 18,850 | -14.1% | 0.01% | -58.1% |
| Q1 2018 | $2,332,000 | +501.0% | 21,945 | -2.9% | 0.03% | +287.5% |
| Q3 2016 | $388,000 | – | 22,593 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |